Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Censavudine - Oncolys Biopharma

Drug Profile

Censavudine - Oncolys Biopharma

Alternative Names: 4'-Ethynyl-d4T - Oncolys BioPharma; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; OBP-601

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kagoshima University; Yale University
  • Developer Bristol-Myers Squibb
  • Class Antivirals; Furans; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Aug 2017 Censavudine is still at phase II development stage for HIV-1 infections in countries worldwide (PO) (Oncolys BioPharma pipeline, August 2017)
  • 29 Jun 2017 Oncolys BioPharma completes a phase II trial in HIV infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top